A recent study from the Mayo Clinic, published in JAMA Neurology, suggests that a simple blood test could help predict which seniors are likely to experience cognitive decline over the next five to ten years. Researchers measured levels of phosphorylated tau 217 (p‑tau217) in the blood of 2,178 cognitively unimpaired adults aged 60 to 90.
How the test works
The participants, drawn from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Neuroimaging Initiative, underwent blood biomarker testing, genetic testing for the APOE ε4 variant, and a series of cognitive assessments. By combining p‑tau217 levels with age, gender and APOE status, the team created a risk‑prediction model.
Key findings
Age proved to be the strongest predictor. For individuals with the same elevated p‑tau217 level, a 65‑year‑old faced an estimated five‑year risk of mild cognitive impairment of about 6%, while an 85‑year‑old’s risk rose to roughly 37%. The presence of the APOE ε4 variant added only a modest increase in risk once p‑tau217 was accounted for.
Senior author Dr. Clifford Jack Jr., a neuroradiologist at the Mayo Clinic, explained that the test “tells you, just by taking a blood sample, whether someone has that pathology in the brain.” Higher p‑tau217 levels were associated with a greater chance of progressing from normal cognition to impairment.
Potential advantages
Detecting p‑tau217 in blood is less invasive and potentially more scalable than current PET scans that measure amyloid burden, a hallmark of Alzheimer’s disease. First author Alicia Algeciras‑Schimnich, Ph.D., said the goal is to give patients a personalized risk estimate that goes beyond a simple positive or negative result for amyloid pathology.
Limitations and next steps
While the findings are promising, the researchers caution that the model was developed using data from southeast Minnesota, a population that may not represent the entire United States. Dr. Jack emphasized the need for replication in other regions before broader use.
Importantly, the test is not yet ready for routine screening of asymptomatic individuals. “There is no treatment that’s been approved for people who are asymptomatic but have the disease in the brain,” Dr. Jack noted. “Therefore, there’s no reason to do the test now, as the results would not change medical management.”
The team added that if preventive therapies become available, the blood test could become a valuable tool for clinicians and patients to discuss potential benefits and risks of treatment.
What this means for seniors
For now, the study underscores that many older adults with low‑level brain pathology may never develop symptoms, and some may pass away from other causes before cognitive impairment appears. As research continues, the hope is that early detection combined with effective preventive treatments could help preserve cognitive health for more seniors.
Original reporting: Fox News (HLL/CB) — read the source article.